Feature | Left Atrial Appendage (LAA) Occluders | September 07, 2017

Closure of Left Atrial Appendage During Heart Surgery Protects the Brain

LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.


September 7, 2017 — Closure of the left atrial appendage (LAA) during heart surgery protects the brain, according to late-breaking research presented today in a Hot Line Late-breaking Clinical Trial session at he European Society of Cardiology (ESC) Congress. The results of the The Left Atrial Appendage Closure by Surgery (LAACS) study suggest that LAA closure should be routinely added to open heart surgery.

“This is the first randomized study to show that closure of the left atrial appendage during open heart surgery effectively protects against brain infarctions and stroke,” said Associate Prof. Helena Domínguez, the cardiologist who designed the study.

“A stroke following open heart surgery can have devastating consequences for patients and their families,” said principal investigator Dr. Park-Hansen, from the Department of Cardiology at Bispebjerg/Frederiksberg University Hospital, Copenhagen, Denmark. “Expectations of returning to work and having improved quality of life after surgery can suddenly turn into early retirement, hospitalizations and prolonged rehabilitation.”

It is well known that atrial fibrillation often occurs after heart surgery and increases the risk for subsequent stroke. Patients may have no symptoms and therefore be unaware that they have atrial fibrillation. Without prophylactic oral anticoagulation treatment, patients remain at risk of blood clotting which can provoke embolic injuries such as strokes.

Blood clots predominantly form in the left atrial appendage, a small sac in the wall of the left atrium of the heart. Some heart surgeons close the left atrial appendage to protect against stroke, particularly in patients with a history of atrial fibrillation, yet there is little evidence to support the efficacy and safety of this practice. No randomized study to date has shown whether left atrial appendage closure can prevent ischemic brain damage.

The LAACS study tested the hypothesis that left atrial appendage closure during open heart surgery would minimize long term ischaemic brain damage. The study prospectively enrolled 187 patients referred for open heart surgery (coronary artery bypass grafting, valve surgery, or both). Patients were randomized to surgical closure of the left atrial appendage (101 patients) or no closure (86 patients).

The primary endpoint was the occurrence of stroke/transient ischemic attack (TIA) or silent cerebral infarction demonstrated on magnetic resonance imaging (MRI) or clinical follow-up. Patients underwent brain MRI before surgery, shortly after discharge, and six months or longer after surgery.

Out of the total randomized cohort, 19 patients reached the combined endpoint during an average follow-up of 3.65 years. The cumulative probability of an ischemic event in the brain was consistently lower in the closed, compared to the not-closed, group (figure 1).

In the intention-to-treat analysis, the proportion of patients meeting the combined endpoint was 16.3% (14 of 86) in the control group and 5% (5 of 101) in the left atrial appendage closure group (hazard ratio [HR] 0.3; 95% confidence interval [CI] 0.1–0.8; p = 0.0197).

Of 187 patients randomized, 141 followed their assigned protocol. Deviations from the protocol were primarily decided by the surgeon, for example refraining from extra procedures in technically complicated operations. In the per protocol analysis, the proportion of patients who met the combined endpoint was 18.2% (14 of 77) in the control group, and 6.3% (4 of 64) in the closure group (HR 0.3; 95% CI 0.1–1.0; p = 0.0465). All but one of the patients in the control group with ischemic events had recurrent atrial fibrillation during follow-up.

“More than three years after open heart surgery, patients who also had left atrial appendage closure were significantly less likely to have strokes or symptomless signs of blood clots in the brain, so-called silent strokes, than the control group,” Park-Hansen said.

He concluded: “Based on the LAACS study, it would be advisable to systematically add surgical closure of the left atrial appendage to planned open heart surgery. Our results need to be replicated in larger cohorts that can also confirm the safety of the procedure.”

Read the related article "Update for LAA Occluder Technology News and Trends."
 

Read about other late-breakers in the article “Late-breaking Trial Presentations at ESC 2017.”


Related Content

News | Atrial Fibrillation

July 8, 2024 — Pulsed field ablation (PFA) is safe for treating patients with common types of atrial fibrillation (AF) ...

Home July 08, 2024
Home
News | Atrial Fibrillation

June 12, 2024 — A team of Ochsner Health cardiologists recently published an article in the Journal of the American ...

Home June 12, 2024
Home
News | Atrial Fibrillation

April 18, 2024 — New evidence-based research calls into question the conventional three-month blanking period ...

Home April 18, 2024
Home
News | Atrial Fibrillation

March 28, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson ...

Home March 28, 2024
Home
News | Atrial Fibrillation

February 27, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & ...

Home February 27, 2024
Home
News | Atrial Fibrillation

February 6, 2024 — Cortex announced the initiation of its RESOLVE-AF trial (NCT05883631), a study formally launched in ...

Home February 06, 2024
Home
News | Atrial Fibrillation

February 2, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson ...

Home February 02, 2024
Home
News | Atrial Fibrillation

January 18, 2024 — Abbott announced the first global procedures have been conducted using the company's new Volt Pulsed ...

Home January 18, 2024
Home
News | Atrial Fibrillation

December 29, 2023 — Boston Scientific Corporation has initiated the AVANT GUARD clinical trial to evaluate the safety ...

Home December 29, 2023
Home
News | Atrial Fibrillation

December 26, 2023 — Pulse Biosciences, Inc., a company primarily focused on leveraging its novel and proprietary CellFX ...

Home December 26, 2023
Home
Subscribe Now